clinical trial · NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Bristol-Myers Squibb·—·recruiting·n = 50
Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaMultiple MyelomaIdecabtagene vicleucelLisocabtagene maraleucel
brief summary
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
started
Oct 6, 2023
primary completion
Oct 6, 2038
completion
Oct 6, 2038
last updated
Jan 22, 2026
official title
Protocol for Transgene Assay Service
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol